Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CTSV | O60911 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632650 | 0.86 | RHEB (0.45) | SRD5A2NSD2AS3MTSGMS2 | |
| SCHEMBL16632405 | 0.86 | SRD5A2 (0.52) | SRD5A2TDP1MAPTMAPK1L3MBTL1 | |
| SCHEMBL16634402 | 0.81 | RHEB (0.53) | SRD5A2TDP1MAPTMAPK1L3MBTL1 | |
| SCHEMBL9593980 | 0.80 | SRD5A2 (0.60) | SRD5A2TDP1MAPTMAPK1L3MBTL1 | |
| SCHEMBL16632588 | 0.80 | SRD5A2 (0.43) | SRD5A2TDP1MAPTMAPK1L3MBTL1 | |
| SCHEMBL16632340 | 0.77 | SRD5A2 (0.54) | SRD5A2ALDH1A1CTSVCTSLDHODH | |
| SCHEMBL16632761 | 0.72 | SRD5A2 (0.55) | SRD5A2TDP1MAPTMAPK1L3MBTL1 | |
| SCHEMBL30954323 | 0.70 | SRD5A2 (0.70) | SRD5A2MAPTMAPK1CYP1A2CYP2C19 | |
| SCHEMBL3052997 | 0.70 | SRD5A2 (0.70) | SRD5A2MAPTMAPK1CYP1A2CYP2C19 | |
| SCHEMBL16640618 | 0.70 | MAPK1 (0.39) | TDP1MAPTMAPK1L3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | SRD5A2 1884/4885TDP1 548/4885MAPT 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.